Novavax (NASDAQ: NVAX) has mentioned that its Covid-19 shot is 89.3% efficient, based mostly on interim information from its part Three scientific trials performed within the U.Ok. The corporate expects to file for emergency authorization with U.Ok. regulators within the coming months. Whereas the reported ef www.nasdaq.com
Novavax (NASDAQ: NVAX) has mentioned that its Covid-19 shot is 89.3% efficient, based mostly on interim information from its part Three scientific trials performed within the U.Ok. The corporate expects to file for emergency authorization with U.Ok. regulators within the coming months. Whereas the reported ef
www.nasdaq.com